135 related articles for article (PubMed ID: 38098510)
1. Definition of bulky disease in early stage diffuse large B-cell lymphoma in computed tomography on coronal and transverse planes.
Ma'koseh M; Farfoura H; Khatib Y; Omari Z; Ababneh H; Fayoumi BA; Taqash A; Al-Rwashdeh M; Abufara A; Shahin O; Halahleh K; Al-Rabi K
Front Oncol; 2023; 13():1063438. PubMed ID: 38098510
[TBL] [Abstract][Full Text] [Related]
2. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.
Kumar A; Burger IA; Zhang Z; Drill EN; Migliacci JC; Ng A; LaCasce A; Wall D; Witzig TE; Ristow K; Yahalom J; Moskowitz CH; Zelenetz AD
Haematologica; 2016 Oct; 101(10):1237-1243. PubMed ID: 27390360
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
4. Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP.
Ma'koseh M; Farfoura H; Abufara A; Elmusa R; Hushki A; Faqeer N; Ghatasheh H; Shahin O; Alawabdeh T; Al-Rwashdeh M; Halahleh K; Al-Ibraheem A; Alrabi K
Hematology; 2023 Dec; 28(1):2198898. PubMed ID: 37114663
[TBL] [Abstract][Full Text] [Related]
5. Improved Progression-Free Survival for Bulky and Non-Bulky Advanced Stage Diffuse Large B-Cell Lymphoma With Consolidative Radiation Therapy: A Bi-Institutional Analysis.
Syed YA; Jiang C; Switchenko J; Kirmani K; Kelsey C; Khan MK
Cureus; 2021 Aug; 13(8):e17107. PubMed ID: 34527492
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass.
Takasaki H; Yamamoto W; Ishii Y; Takahashi H; Watanabe R; Harada T; Kawasaki R; Hashimoto C; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
Indian J Hematol Blood Transfus; 2015 Sep; 31(3):346-51. PubMed ID: 26085719
[TBL] [Abstract][Full Text] [Related]
7. Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment.
Jin H; Jin M; Lim CH; Choi JY; Kim SJ; Lee KH
Front Oncol; 2023; 13():1186311. PubMed ID: 37384292
[TBL] [Abstract][Full Text] [Related]
8. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
11. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
12. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
13. MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients.
Wang Y; Liu D; Zhang X; Zhang M; Li S; Feng X; Dong M; Ma S; Qian S; Wang Z; Zhang Y; Wang P; Mei S; Chen Q
Cancer Med; 2023 Sep; 12(18):18568-18577. PubMed ID: 37641492
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP.
Halahleh K; Yaseen A; Muradi I; Al-Ibraheem A; Sultan I; Ma'koseh M
J Blood Med; 2023; 14():147-157. PubMed ID: 36846350
[TBL] [Abstract][Full Text] [Related]
16. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
17. Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Younes S; Yoo C; Wignarajah A; Jin M; Guo HH; Gupta NK; Natkunam Y; Advani RH; Hoppe RT
Leuk Lymphoma; 2021 Aug; 62(8):1840-1849. PubMed ID: 33622155
[TBL] [Abstract][Full Text] [Related]
18. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.
Chohan KL; Young JR; Lester S; Alhaj Moustafa M; Rosenthal A; Tun HW; Hoppe BS; Johnston PB; Micallef IN; Habermann TM; Ansell SM
Blood Adv; 2022 Jul; 6(14):4241-4250. PubMed ID: 35617689
[TBL] [Abstract][Full Text] [Related]
19. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
20. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
